Print
contact ussite map
Juvaris Beotherapeutics, Inc.

Overview of Juvaris' Technology Platform

The Juvaris technology platform consists of cationic lipid-DNA complexes in development to treat infectious diseases and cancers. The DNA component contains immunostimulatory CpGs and non-CpG motifs, but does not code for any genes and is thereby distinguished from gene therapy and traditional DNA vaccine technologies. The Company is developing adjuvanted vaccines and immunotherapies employing its lead compound JVRS-100.

^ back to top

© 2014 Juvaris BioTherapeutics.